The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized ...

Only with the adoption of digital imaging and AI-powered analysis will next-generation precision oncology therapies reach ...

DCIS is a non-invasive or pre-invasive breast cancer, meaning the cancer cells are confined to the milk ducts and haven’t ...

Olivia Munn has come a long way with her personal experience of breast cancer. Having informed the world of her diagnosis in ...

The 'Your Friends & Neighbors' star said she and her mom were there for each other for both of their double mastectomy surgeries: "There's something about watching a loved one go through it that is ...

Olivia Munn is opening up about her mom's breast cancer diagnosis. The "Your Friends and Neighbors" star, 45, took to ...

In March 2024, the Your Friends & Neighbors actress announced she had been diagnosed with breast cancer and had undergone ...

In one of the first large-scale analyses of antibody-drug conjugates (ADCs) by race, a study presented at the recent American Society of Clinical Oncology (ASCO) meeting found that Black patients with ...

Arturo Loaiza-Bonilla, MD, MSEd, systemwide chief of hematology and oncology at St. Lukes University Health Network and ...

A new nanozyme-antibody platform selectively targets HER2-positive tumors, disrupting gene expression and reducing metastasis ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.